With Pfizer struggling in 2023, CEO Bourla hit with 35% pay cut to $21.6M

Pfizer knew 2023 was going to be a challenging year of transition. But even the drugmaker was surprised by the plummeting demand for its COVID-19 products, missing badly on its 2023 guidance. When the year was over, the company’s revenue was down 41% and its shares had plunged by 44%.